If you have been reading about regulatory status and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-11. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
=== Modified Miller–Urey experiments === Much work has been done since the 1950s toward understanding how Miller–Urey chemistry behaves in various environmental settings. Different atmospheric compositions. In 1983, testing different atmospheric compositions, Miller and another researcher repeated experiments with varying proportions of H2, H2O, N2, CO2 or CH4, and sometimes NH3. They found that the presence or absence of NH3 in the mixture did not significantly impact amino acid yield, as NH3 was generated from N2 during the spark discharge. Additionally, CH4 proved to be one of the most important atmospheric ingredients for high yields, likely due to its role in HCN formation. Much lower yields were obtained with more oxidized carbon species in place of CH4, but similar yields could be reached with a high H2/CO2 ratio. Thus, Miller–Urey reactions work in atmospheres of other compositions as well, depending on the ratio of reducing and oxidizing gases. Role of nitrites and calcium carbonate. More recently, Jeffrey Bada and H. James Cleaves, graduate students of Miller, hypothesized that the production of nitrites, which destroy amino acids, in CO2 and N2-rich atmospheres may explain low amino acids yields. In a Miller–Urey setup with a less-reducing (CO2 + N2 + H2O) atmosphere, when they added calcium carbonate to buffer the aqueous solution and ascorbic acid to inhibit oxidation, yields of amino acids greatly increased, demonstrating that amino acids can still be formed in more neutral atmospheres under the right geochemical conditions.
Following the release of his mixtape Hologram Panda with producer Dame Grease, Riff Raff told MTV that his upcoming Mad Decent second studio album would be titled Riff Raff, The Neon Icon, later shortened to Neon Icon. In February 2013 he told Complex that his second studio album is due out some time during the third quarter of 2013. On June 25, 2013, he released a single titled "Dolce & Gabbana", produced by DJ Carnage as the first single from Neon Icon, however two days later he announced that the song wouldn't be included on the album. He was also featured on Far East Movement's single "The Illest" around the same time. Then on July 12, 2013, he released another non album single titled "Mr. Popular", and four days later released the music video for the song. In August 2013, Riff Raff announced that he would be releasing a collaboration album with Action Bronson titled Galaxy Gladiators in 2014. On November 26, 2013, he released the first official single for Neon Icon titled "How To Be the Man" and produced by DJ Mustard. That same month, Riff Raff told Rolling Stone in an interview that leading up to the album's release he would release various "left-over" tracks from the album's recording sessions These notably included the Boi-1da produced "Real Boyz", featuring rappers OJ da Juiceman and Cap 1, as well as "Suckas Askin' Questions" with Lil Debbie and "Shoulda Won a Grammy" with Action Bronson. In March 2014, prior to the album's release, Rolling Stone included the album on their list of "27 Must-Hear Albums of 2014".
Prediabetes is a component of metabolic syndrome and is characterized by elevated blood sugar levels that fall below the threshold to diagnose diabetes mellitus. It usually does not cause symptoms, but people with prediabetes often have obesity (especially abdominal or visceral obesity), dyslipidemia with high triglycerides and/or low HDL cholesterol, and hypertension. It is also associated with increased risk for cardiovascular disease (CVD). Prediabetes is more accurately considered an early stage of diabetes, as health complications associated with type 2 diabetes often occur before the diagnosis of diabetes. Prediabetes can be diagnosed by measuring hemoglobin A1c, fasting glucose, or glucose tolerance test. Many people may be diagnosed through routine screening tests. The primary treatment approach includes lifestyle changes such as exercise and dietary adjustments. Some medications can be used to reduce the risks associated with prediabetes. There is a high rate of progression to type 2 diabetes but this does not develop for everyone with prediabetes. Prediabetes can be a reversible condition with lifestyle changes. For many people, prediabetes and diabetes are diagnosed through a routine screening at a check-up. The earlier prediabetes is diagnosed, the more likely an intervention will be successful.
Sources: en.wikipedia.org
Castor oil is a vegetable oil pressed from castor beans, the seeds of the plant Ricinus communis. The seeds are 40 to 60 percent oil. It is a colourless or pale yellow liquid with a distinct taste and odor. Its boiling point is 313 °C (595 °F) and its density is 0.961 g/cm3. It includes a mixture of triglycerides in which about 90 percent of fatty acids are ricinoleates. Oleic acid and linoleic acid are the other significant components. Some 270,000–360,000 tonnes (600×10^6–790×10^6 lb) of castor oil are produced annually for a variety of uses, including soaps, lubricants, hydraulic and brake fluids, paints, dyes, coatings, inks, cold-resistant plastics, waxes and polishes, nylon, and perfumes.
=== NNPC Bags Transparency Award === The efforts of the Mallam Mele Kyari-led Management of the Nigerian National Petroleum Corporation (NNPC) to entrench the culture of transparency in the system have begun to receive recognition with the Corporation named as the “Government Agency of the Year 2020 (Transparency)” by the New Telegraph.
Cliffe began directly contacting Half-Life mappers and reached out to people who had previously submitted maps to Radium, a Half-Life mapping site. A contest was held to select maps for the initial beta, though some maps selected were later discarded. Before the first beta's official release, a pre-beta build was leaked online, which potentially accelerated the release of the mod. The first beta, released on June 18, 1999, featured a hostage rescue scenario, 9 weapons, 4 maps, and one player model per side. Jess Cliffe reported that the release was well received by the community. Beta 2 and Beta 3 followed, adding new weapons, maps, and factions. Beta 3 introduced the removal of kill counts from the scoreboard, which was controversial and later reversed. Beta 4 introduced the bomb defusal scenario. The interest in the game drew numerous players to Cliffe's website, which helped both him and Le make revenue from advertisements hosted on the site. Another website related to Counter-Strike, a fansite named CS-Nation, was launched by John "rizzuh" Jensen as a source for information about the game, news updates, and skins. In late 1999, Minh Le began working at Barking Dog Studios while finishing his studies. When Valve Software learned of this, they asked Barking Dog to assist in developing Beta 5, offering to finance the project and acquire the game's intellectual property. Barking Dog mainly handled development, as Le was occupied with his university studies. Valve contributed by cleaning up code, fixing bugs, and enhancing the interface.
==== Biomolecules ==== The isotopic composition of biomolecules preserved in the sedimentary record can be used as a proxy for paleoenvironment reconstructions. Since water is the main hydrogen source for photoautotrophs, the HIC of their biomass can be related to the composition of their growth water and thereby used to gain insight into some properties of ancient environments. Studying hydrogen isotopes can be very valuable, as hydrogen is more directly related to climate than other relevant stable isotope systems. However, hydrogen atoms bonded to oxygen, nitrogen, or sulfur are exchangeable with environmental hydrogen, which makes this system less straightforward [ref to earlier H exchange section]. To study the HIC of biomolecules, it is preferable to use compounds where the hydrogen is largely bound to carbon, and thus not exchangeable on experimental timescales. By this criterion, lipids are a much better subject for hydrogen isotope studies than sugars or amino acids. The net fractionation between source water and lipids is denoted εl/w:
Sources: en.wikipedia.org
In October 2016, he was selected as a "full member" of the Royal College of Physicians of Edinburgh, one of only a handful of Turkish nationals to receive that honor, marked by a ceremony in which Okan's membership diploma was bestowed upon him by then-President of the Royal College, and later director of the National Institute for Health Research, Derek Bell. In November 2020, he was awarded an FRCP from the Royal College of Physicians of London, and in January 2021 awarded an FRCP from the Royal College of Physicians of Ireland. In his early days, he started his career as a dermatologist at Acibadem Bakirkoy Hospital and later worked Medical Park Hospital and Memorial Bahcelievler Hospital as an associate professor and also as a skin diseases specialist. He founded and chaired the Dermatology Department at Istanbul Kemerburgaz University in 2013. He volunteered with Health Volunteers Overseas as part of the Dermatology program at Preah Kossamak Hospital, Phnom Penh, Cambodia. He assisted in the training of dermatology students, provided continuing education regarding current and new trends of dermatologic diagnosis and treatment and provided training to nurses and physicians involved in dermatologic care. In 2021, Okan and his team reported their findings that psoriasis patients had unusually high levels of neurofilament and Tau protein, which act as a skeleton in the nerve cells in these patients. These levels were higher than those of non-sick individuals, especially when compared to the levels of those with severe psoriasis under the age of 40.
Scutellaria is a genus of flowering plants in the mint family, Lamiaceae. They are known commonly as skullcaps. The generic name is derived from the Latin scutella, meaning "a small dish, tray or platter", or "little dish", referring to the shape of the calyx. The common name alludes to the resemblance of the same structure to "miniature medieval helmets". The genus has a subcosmopolitan distribution, with species occurring nearly worldwide, mainly in temperate regions.
=== Interferon === Interferons are produced by the immune system. They are usually involved in anti-viral response, but also have use for cancer. They fall in three groups: type I (IFNα and IFNβ), type II (IFNγ) and type III (IFNλ). IFNα has been approved for use in hairy-cell leukaemia, AIDS-related Kaposi's sarcoma, follicular lymphoma, chronic myeloid leukaemia and melanoma. Type I and II IFNs have been researched extensively and although both types promote anti-tumor immune system effects, only type I IFNs have been shown to be clinically effective. IFNλ shows promise for its anti-tumor effects in animal models. Unlike type I IFNs, Interferon gamma is not approved yet for the treatment of any cancer. However, improved survival was observed when Interferon gamma was administered to patients with bladder carcinoma and melanoma cancers. The most promising result was achieved in patients with stage 2 and 3 of ovarian carcinoma. The in vitro study of IFN-gamma in cancer cells is more extensive and results indicate anti-proliferative activity of IFN-gamma leading to the growth inhibition or cell death, generally induced by apoptosis but sometimes by autophagy.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.